**CERTIFICATE OF ANALYSIS**

**CERTIFICATE No:**  CAN/2015-16/XYZ

|  |  |  |  |
| --- | --- | --- | --- |
| **PRODUCT** | NEVIRAPINE TABLETS, USP 200 mg | | REF. NO: NDQD201508142 |
| **DATE RECEIVED:** 06.08.2015 | **LABEL CLAIM:** | Each tablet contains 200 mg of Nevirapine USP. | |
| **BATCH NO.:** E141785 | **PRESENTATION:** | White colored, caplet shaped, biconvex faced tablets, single scored on both faces and embossed with "H" and "7" on either side of the scored opposite faces, packet in a white plastic multi-dose container carrying 60 tablets in a unit box. | |
| **MGF. DATE:** Oct. 2014 | **MANUFACTURER:** | HETERO Labs Limited. | |
| **EXP. DATE:** Sep. 2019 | **ADDRESS:** | 22 - 110, I.D.A., Jeedimetla, Hyderabad - 500 055, INDIA. | |
| **CLIENT REF NO:** | **CLIENT:** | National AIDS and STI Control Programme P.O. BOX 19361 Nairobi | |
|  | **TEST(S) REQUESTED:** | Uniformity of Weight, Identification, Dissolution, Assay | |

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **TEST** | **METHOD** | **COMPEDIA** | **SPECIFICATION** | **DETERMINED** | **REMARKS** |
| **Uniformity of Weight** | Weight | B.P. 2012 Vol. V App XII C | NMT 2 tablets deviate by more than 5% from mean weight | None Deviates | **COMPLIES** |
| **Identification** | HPLC | Adopted In-House Method | RT of the major peak in the assay sample preparation corresponds to that in the assay standard preparation | Super-imposable peak at RT 5.4 Â± 10% min. present in both the assay sample and standard preparations | **COMPLIES** |
| **Dissolution** | HPLC | Adopted In-House Method | No tablet less than 80% [n = 6] | 102.3% (RSD = 2.5%; n = 6) | **COMPLIES** |
| **Assay** | HPLC | Adopted In-House Method | 90.0 - 110.0% | 101.4% (RSD = 0.5%; n = 9) | **COMPLIES** |

**CONCLUSION:** The product complies with the specifications for the tests performed.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  |  | DATE: |
| DIRECTOR: | HEZEKIAH CHEPKWONY |  | DATE:11-05-2015 |